Psychiatry · Orlando, FL
NPI
1588805824
Since 2009
Specialty
Psychiatry
Code 2084P0800X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1836 Woodward St
Orlando, FL, 32803
Phone (407) 883-9303
Groups this clinician bills Medicare through
Medicare paid, 2024
$148K
1,382 services
Medicare patients, 2024
290
Average age 75
Drug cost, 2024
$2.3M
9,790 prescriptions
Company payments, 2025
$70K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David A Medina was code 99350 (home e&m - new and established), 324 times for 132 patients. In total David A Medina billed 1,382 services in 17 codes, and Medicare paid $148K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-07-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99350 Home E&M - New and Established | Office | 324 | 132 | $141.87 | $46K |
| 90836 Psychotherapy - Nongroup | Office | 243 | 63 | $70.28 | $17K |
| 99214 Office E&M - Established | Office | 210 | 57 | $92.53 | $19K |
| 99349 Home E&M - New and Established | Office | 208 | 102 | $94.20 | $20K |
| 99215 Office E&M - Established | Office | 117 | 36 | $138.97 | $16K |
| 99310 SNF E&M | Facility | 86 | 32 | $116.58 | $10K |
| 90833 Psychotherapy - Nongroup | Office | 84 | 40 | $51.72 | $4,344 |
| 99345 Home E&M - New and Established | Office | 42 | 42 | $153.18 | $6,434 |
| 99205 Office E&M - New | Office | 19 | 19 | $172.27 | $3,273 |
| 90847 Psychotherapy - Nongroup | Office | 19 | 18 | $79.35 | $1,508 |
By year: 2022 $170K for 1,626 services; 2023 $185K for 1,838 services; 2024 $148K for 1,382 services.
Medicare prescription drug claims, 2024
In 2024, the drug David A Medina prescribed most often to Medicare patients was Quetiapine Fumarate, with 881 prescriptions and refills. In total David A Medina wrote 9,790 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Quetiapine Fumarate Generic | 881 | 1,201 | 149 | $21K |
| Clonazepam Generic | 849 | 864 | 114 | $8,000 |
| Alprazolam Generic | 784 | 792 | 107 | $5,111 |
| Risperidone Generic | 415 | 441 | 39 | $8,625 |
| Lorazepam Generic | 409 | 413 | 54 | $4,175 |
| Sertraline Hcl Generic | 338 | 474 | 60 | $3,289 |
| Trazodone Hcl Generic | 305 | 408 | 51 | $4,940 |
| Benztropine Mesylate Generic | 283 | 295 | 31 | $4,231 |
| Temazepam Generic | 282 | 290 | 33 | $2,272 |
| Aripiprazole Generic | 235 | 307 | 39 | $9,978 |
| Buspirone Hcl Generic | 225 | 319 | 39 | $5,836 |
| Zolpidem Tartrate Generic | 223 | 225 | 34 | $1,531 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 187 | 187 | 21 | $5,525 |
| Belsomra Suvorexant | 185 | 201 | 30 | $88K |
| Divalproex Sodium Generic | 184 | 203 | 23 | $7,888 |
Brand drugs: 1,003 claims; generic drugs: 8,787 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David A Medina $70K ($70K in general payments such as food, travel and fees) from 25 companies. The largest payer was Neurocrine BioSciences, Inc. with $49K.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 103 | $49K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 22 | $15K |
| Axsome Therapeutics, Inc. AXSM | 25 | $1,054 |
| E.R. Squibb & Sons, L.L.C. BMY | 21 | $744 |
| Teva Pharmaceuticals USA, Inc. TEVA | 22 | $648 |
| Abbvie Inc. ABBV | 17 | $498 |
| Alkermes, Inc. ALKS | 25 | $490 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 12 | $450 |
| Vanda Pharmaceuticals Inc. VNDA | 13 | $336 |
| Janssen Pharmaceuticals, Inc JNJ | 8 | $299 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.